IFNλ在乙型肝炎治疗中的意义及相关研究进展  

Research progress on interferon λ in chronic hepatitis B

作　　者：叶婵媛 张珊妍 章晓莉 顾珏清 杨益大[1] Ye Chanyuan;Zhang Shanyan;Zhang Xiaoli;Gu Jueqing;Yang Yida(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院传染病诊治国家重点实验室,国家感染性疾病临床医学研究中心,感染性疾病诊治协同创新中心,杭州310003

出　　处：《中华临床感染病杂志》2020年第3期228-233,共6页Chinese Journal of Clinical Infectious Diseases

基　　金：国家"十三五"科技重大专项(2017ZX10202202)。

摘　　要：乙型肝炎是我国主要的公共卫生问题。核苷(酸)类似物和干扰素(IFN)两大类药物能够有效抑制HBV的复制,但由于不能彻底清除cccDNA,治疗效果仍不甚满意。IFNλ是新发现的一类细胞因子家族,通过激活Jak-STAT通路从而诱导抗病毒、抗增殖、抗肿瘤作用。近年来研究发现,IFNλ作为一种治疗手段及免疫学指标在乙型肝炎中具有重要意义,IFNλ可有效抑制HBV的复制,其基因多态性与乙型肝炎的预后及易感性密切相关,且IFNλ在乙型肝炎相关的肝细胞癌中也表现出一定的抗肿瘤活性,有望用于临床上乙型肝炎患者的辅助治疗。本文就目前IFNλ在乙型肝炎中的意义及相关研究进展进行阐述。Hepatitis B is a major public health problem in China.Nucleoside/nucleotide analogues and interferon(IFN)can effectively inhibit the replication of hepatitis B virus,but the treatment effect is still not so effective because cccDNA cannot be completely removed.IFNλis a newly discovered family of cytokines that induces antiviral,antiproliferative and antitumor effects by activating the Jak-STAT pathway.Recent studies have found that IFNλis also of great significance in hepatitis B as a therapeutic agent and immunological indicator.IFNλcan effectively inhibit the replication of hepatitis B virus,while the gene polymorphisms of IFNλare closely related to prognosis and susceptibility to hepatitis B;and IFNλalso shows a certain anti-tumor activity in hepatitis B-related hepatocellular carcinoma.IFNλis expected to be used as a clinical adjuvant treatment for patients with hepatitis B.This article describes the current research progress on IFNλin hepatitis B.

关 键 词：肝炎 乙型 慢性 干扰素λ 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]